Seelos Therapeutics rises on nod to begin neurodisease drug study in Australia

Seelos Therapeutics

08/03/2022 14:17

** Drug developer's shares  SEEL.O  up 2.8% at 95 cents
before the bell 
    ** Stock on track to snap its two-day losing streak if gains
hold 
    ** Co receives authorization to begin mid-stage study of its
drug to treat nervous system disorders SLS-005 in Australia
 urn:newsml:reuters.com:*:nPn8scJQ8a
    ** SLS-005 is being tested as a potential treatment for
certain neurological disorders including Huntington's disease  
    ** SEEL receives acknowledgment letter for a pilot study of
SLS-005 in Alzheimer's patients from Australia's regulatory body
for clinical trials 
    ** Up to Monday's close, stock was down 43.3% YTD 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))